Megan H Noe1, Olaf Rodriguez2, Laura Taylor3, Laith Sultan4, Chandra Sehgal4, Susan Schultz4, Joel M Gelfand1,5, Marc A Judson6, Misha Rosenbach1. 1. Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia. 2. Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA USA. 3. Department of Pathology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA USA. 4. Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA USA. 5. Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA USA. 6. Department of Medicine, Division of Pulmonary and Critical Care Medicine, Albany Medical Center, Albany NY USA.
Abstract
BACKGROUND: As is the case for many skin diseases, cutaneous sarcoidosis does not currently have an objective measure of disease burden to establish disease severity and response to treatment. The disease has traditionally been assessed by visual skin changes, including induration and erythema; however, such assessments may fail to quantify the total skin granuloma burden, as the majority of the granulomatous inflammation may lie deep within the dermis and not be reliably detected by sight or palpation. OBJECTIVES: The purpose of this pilot study is to evaluate the feasibility of high frequency ultrasound as an objective measure of granuloma burden in cutaneous sarcoidosis and to compare high frequency ultrasound to a previously validated clinical instrument (CSAMI) and histopathology evaluation. RESULTS: A strong correlation was observed between the mean brightness of high frequency ultrasound images and both the lesional CSAMI score (Spearman's rho: 0.9710, p = 0.0012) and percent of dermis with granulomas histopathology (Spearman's rho: 0.8407 p = 0.0361). CONCLUSIONS: These results confirm high frequency ultrasound is a valid, objective measure of granuloma burden in cutaneous sarcoidosis and represents a novel, non-invasive measure of disease severity that correlates to the previously validated CSAMI clinical severity score and histopathology evaluation.
BACKGROUND: As is the case for many skin diseases, cutaneous sarcoidosis does not currently have an objective measure of disease burden to establish disease severity and response to treatment. The disease has traditionally been assessed by visual skin changes, including induration and erythema; however, such assessments may fail to quantify the total skin granuloma burden, as the majority of the granulomatous inflammation may lie deep within the dermis and not be reliably detected by sight or palpation. OBJECTIVES: The purpose of this pilot study is to evaluate the feasibility of high frequency ultrasound as an objective measure of granuloma burden in cutaneous sarcoidosis and to compare high frequency ultrasound to a previously validated clinical instrument (CSAMI) and histopathology evaluation. RESULTS: A strong correlation was observed between the mean brightness of high frequency ultrasound images and both the lesional CSAMI score (Spearman's rho: 0.9710, p = 0.0012) and percent of dermis with granulomas histopathology (Spearman's rho: 0.8407 p = 0.0361). CONCLUSIONS: These results confirm high frequency ultrasound is a valid, objective measure of granuloma burden in cutaneous sarcoidosis and represents a novel, non-invasive measure of disease severity that correlates to the previously validated CSAMI clinical severity score and histopathology evaluation.
Entities:
Keywords:
disease severity instrument; high frequency ultrasound; non-caesating granuloma; sarcoidosis
Authors: Piotr M Szczypiński; Michał Strzelecki; Andrzej Materka; Artur Klepaczko Journal: Comput Methods Programs Biomed Date: 2008-10-14 Impact factor: 5.428
Authors: Francesco Lacarrubba; Giovanni Pellacani; Silvia Gurgone; Anna Elisa Verzì; Giuseppe Micali Journal: Int J Dermatol Date: 2015-03-13 Impact factor: 2.736
Authors: Robert P Baughman; Marc A Judson; Alvin Teirstein; Elyse E Lower; Kim Lo; Rozsa Schlenker-Herceg; Elliot S Barnathan Journal: Am J Clin Dermatol Date: 2008 Impact factor: 7.403
Authors: Howa Yeung; Sara Farber; Belinda K Birnbaum; Jonathan Dunham; Alexis Ogdie; Karen C Patterson; Aimee S Payne; Mary K Porteous; Milton D Rossman; Rebecca Sharim; Junko Takeshita; Victoria P Werth; Daniel B Shin; Sarah Price; Misha Rosenbach Journal: JAMA Dermatol Date: 2015-12-01 Impact factor: 10.282